Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus

Launched by FEDERAL UNIVERSITY OF SÃO PAULO · Mar 18, 2012

Keywords

ClinConnect Summary

Clinical and autopsy studies show that up to 30% of patients with type 1 diabetes mellitus show a detectable β-cell function at clinical diabetes. The preservation of this endogenous insulin production, even if it is small, can have a great impact on the evolution of long-term disease through improving glycemic control, reducing chronic diabetes complications and hypoglycemia. Strategies for preventing the loss of beta cell are based on stopping the autoimmune process and also in the preservation and regeneration of beta cells. Currently have been questioned the potential use of GLP-1 for n...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 to 35 years
• • Up to 6 months of clinical diagnosis
• • Fasting C-peptide ≥ 0.25 ng / ml
• • HbA1C \<9.0%
• • Positive autoantibodies (anti-GAD, Anti-Insulin and Anti-IA2)
• • Without chronic complications
• Exclusion Criteria:
• • Hepatic, cardiac, pulmonary and hematologic disease